Close C-145-03 HNSCC single therapy study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- by 31 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Close C - 145 - 03 HNSCC single therapy”
What we found
Evidence strength A What the grades mean
The company completed enrollment for the C-145-03 study of LN-145 for HNSCC in 2021, fulfilling the commitment to close the study within the stated timeframe.
-
A Iovance Biotherapeutics, Inc. 10-K filed 2022-02-24
“In 2021, we completed enrollment in an additional study, C-145-03, of LN-145, for recurrent and/or metastatic HNSCC.” ✓ confirmed on the page
Market reaction: the shares moved +7.6% against the S&P 500 over the three sessions around the disclosure (23 Feb 2022 to 28 Feb 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Close
- Deliverable
- C-145-03 HNSCC single therapy study
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Iovance Biotherapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IOVA-021229 · Corrections policy